logo-loader

hVIVO PLC

Receive alerts
Market:
LSE
Market Cap:
£13.11 m
Price
15.75 GBX
Change
-0.94%
52 weeks high
46.42
52 weeks low
13.20

In brief

Established in 1989 as a spin out from Queen Mary University, London, hVIVO listed on AIM in 2012 and is an industry-leading clinical development CRO services business pioneering human disease models based upon viral challenge. Using human challenge studies to establish early proof-of-concept, hVIVO's clinical trial platform can accelerate drug and vaccine development in respiratory and infectious diseases, specifically leveraging hVIVO's established human disease challenge models in influenza (“flu”), respiratory syncytial virus (“RSV”) and human rhinovirus (“HRV”) and more recently the expansion and development of these models in other respiratory indications such as asthma, chronic obstructive pulmonary disease (“COPD”) and cough and in special populations.

AIM: HVO

Deep dive We explore the investor case for growth companies

Snapshot

The challenge trial charts the entire disease life cycle from healthy to sick and back to health.